Integrum AB

Equities

INTEG B

SE0009807266

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 11:29:30 2024-04-26 am EDT			5-day change	1st Jan Change
55.6 ^SEK	+8.17%		-6.08%	+21.80%

Mar. 26	Integrum Enters a Commercial agreement with AMI Technologies to introduce the OPRATM Implant System in Israel	CI
Feb. 29	Integrum AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI

Integrum Enters a Commercial agreement with AMI Technologies to introduce the OPRATM Implant System in Israel

March 26, 2024 at 02:00 am EDT

Integrum (publ) announced that the company has entered a commercial agreement with AMI Technologies, to introduce the OPRATM Implant System in Israel. As part of Integrum's efforts to expand the availability of the OPRA? Implant System to new geographical markets, the company has started a collaboration in Israel with AMI Technologies.

Latest news about Integrum AB

Integrum Enters a Commercial agreement with AMI Technologies to introduce the OPRATM Implant System in Israel	Mar. 26	CI
Integrum AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Feb. 28	CI
Integrum Sells and Delivers Opratm Implant Systems to A Value of SEK 3.5 Million to Center of Excellence in Ukraine	Jan. 31	CI
Integrum AB Establishes Center of Excellence in Ukraine	Dec. 20	CI
Integrum AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 03	CI
Integrum AB Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data	Nov. 13	CI
Integrum AB Provides Earnings Guidance for the Second Quarter of 2023	Nov. 10	CI
Integrum Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations	Nov. 10	CI
Integrum's Opra?? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations	23-10-30	CI
Integrum Enters into the Turkey Market	23-10-27	CI
Integrum Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing	23-10-12	CI
Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI	23-10-12	CI
Integrum Receives Unitary Patent for Neuromotus in the EU	23-10-10	CI
Integrum AB Appoints Scott Flora as Full Board Member	23-10-10	CI
Integrum Initiates A Strategic Review Process to Accelerate Growth	23-09-14	CI
Integrum AB Receives Reimbursement Code for Axor II	23-09-08	CI
Integrum AB Reports Earnings Results for the First Quarter Ended July 31, 2023	23-08-30	CI
Analysis-Small firms offer private equity job market bright spot	23-07-26	RE
Integrum Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand	23-07-13	CI
Integrum AB Announces Management Changes	23-06-16	CI
Integrum AB Reports Earnings Results for the Fourth Quarter Ended April 30, 2023	23-06-08	CI
Integrum AB Reports Earnings Results for the Full Year Ended April 30, 2023	23-06-08	CI
Integrum AB and Collaboration Partners Receive SEK 3.2 Million in Research Grant for Textile-Based Research Project Hope	23-06-01	CI
Integrum Announces the Appointment of Scott Flora as Adjunct Board Member	23-05-11	CI
Integrum AB Moves into New Head Office at GoCo Health Innovation Cit	23-05-03	CI

Chart Integrum AB

Duration

Period

More charts

Company Profile

Integrum AB is a Sweden-based company within healthcare sector. It provides systems for bone-anchored prostheses for individuals with amputations. The Companyâs solutions comprise OPRA Implant System, neural prosthetics, phantom limb pain treatment and prosthetic components. The OPRA implant system is based on osseointegration, enabling the direct connection of an artificial limb to the skeleton. The neural prosthetics technology implies ability to directly connect bionic prostheses to the patientâs bone, nerves, and muscles. A method for limb pain treatment implies motor execution of the phantom limb as a treatment, which is aided by machine learning, augmented and virtual reality. The Company provides a variety of prosthetic components required to connect the OPRA Implant System to external prostheses.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-29 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Integrum AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Prosthetics

	1st Jan change	Capi.
INTEGRUM AB	+21.80%	93.49M
STRAUMANN HOLDING AG	+1.84%	24.07B
COCHLEAR LIMITED	+7.40%	13.7B
DEMANT A/S	+10.34%	10.18B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-17.75%	2.06B
EMBLA MEDICAL HF.	+6.38%	1.79B
ANGELALIGN TECHNOLOGY INC.	+41.47%	1.73B
MODERN DENTAL GROUP LIMITED	+13.26%	589M
ANGEL ROBOTICS CO., LTD.	0.00%	400M
DELCATH SYSTEMS, INC.	+27.40%	135M

Medical Prosthetics